# US 2012/0251630 A1 · Remission therapy of cancer with isoflavonoids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251630 A1
- Document ID: US20120251630A1
- Status: Published application
- Kind: A1
- Application number: 13/434,665
- Filed: 2012-03-29
- Published: 2012-10-04
- Earliest claimed: 2011-03-29
- Assignees: Marshall Edwards, Inc.
- Inventors: Ayesha B. Alvero; Daniel P. Gold; Gil G. Mor
- Web page: https://patentgrep.com/patent/US20120251630A1

## CPC

- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein is a method of reducing incidences of cancer recurrence. The method involves administering to an individual in cancer remission an isoflavonoid. In specific instances, the treated individual is in remission from epithelial cancer, such as ovarian cancer or breast cancer.

## Claims

### Claim 1

A method of reducing incidences of cancer recurrence, comprising administering to an individual in cancer remission an effective amount of a compound of formula (I):
wherein
R1, R3 and R4 are independently hydrogen, hydroxy, halo, haloalkyl, NR12R13, C1-6 alkoxy, C1-6 fluoroalkyl or C1-6 alkyl;
R2 and R5 are independently hydrogen, hydroxy, halo, haloalkyl, NR12R13, C1-6 alkoxy, C1-6 fluoroalkyl or C1-6 alkyl;
R6 is hydrogen;
R7 is hydrogen, haloalkyl, halo or C1-6 alkyl;
R9 is hydroxy or C1-6 alkoxy;
R10 is hydrogen;
the drawing “” and R11 together represent a double bond or the drawing “” represents a single bond and R11 is hydrogen or hydroxy;
R12 and R13 are independently hydrogen, C1-6 alkyl or trialkyl silyl;
or salts or a derivative thereof; and
wherein the compound of formula (I) reduces cancer cell proliferation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound of formula (I) is selected from compounds 1 to 22 as set forth below:
3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol (compound 1);
3-(4-methoxyphenyl)-4-(4-methoxyphenyl)-8-methyl-7-methoxychroman (compound 2);
3-(3,4-dimethoxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol (compound 3);
3-(4-methoxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol (compound 4);
3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-8-methyl-7-methoxychroman (compound 5);
3-(3-methoxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol (compound 6);
3-(3,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-8-methyl-7-methoxychroman (compound 7);
3-(3-hydroxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol (compound 8);
3-(3,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-8-methylchroman-7-ol (compound 9);
3-(3-hydroxyphenyl)-4-(4-methoxyphenyl)-8-bromochroman-7-ol (compound 10);
3-(4-hydroxyphenyl)-4-(4-methoxy-3-methylphenyl)chroman-7-ol (compound 11);
3-(4-hydroxyphenyl)-4-(4-hydroxy-3-methylphenyl)chroman-7-ol (compound 12);
3-(4-hydroxyphenyl)-4-(4-fluoro-3-methylphenyl)chroman-7-ol (compound 13);
3-(4-hydroxyphenyl)-4-(4-methoxy-3-fluorophenyl)chroman-7-ol (compound 14);
3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol (compound 15);
3-(4-hydroxyphenyl)-4-(4-hydroxy-3-methylphenyl)-8-methylchroman-7-ol (compound 16);
3-(4-hydroxyphenyl)-4-(4-methoxy-3-methylphenyl)-8-methylchroman-7-ol (compound 17);
3-(4-hydroxyphenyl)-4-(4-methoxy-3,5-dimethylphenyl)-8-methylchroman-7-ol (compound 18);
3-(4-hydroxyphenyl)-4-(4-fluoro-3-methylphenyl)-8-methylchroman-7-ol (compound 19);
3-(4-hydroxyphenyl)-4-(4-methoxy-3-fluorophenyl)-8-methylchroman-7-ol (compound 20);
3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)chroman-7-ol (compound 21); and
3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)chroman-7-ol (compound 22).

### Claim 3 (depends on 1)

The method of claim 1, wherein the individual is in remission from bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, cancers of the brain or melanoma.

### Claim 4 (depends on 1)

The method of claim 1, wherein the individual is in remission from ovarian cancer or breast cancer.

### Claim 5 (depends on 1)

The method of claim 1, further comprising administering to the individual an anti-cancer agent.

### Claim 6

(canceled)

### Claim 7 (depends on 5)

The method of claim 5, wherein the anti-cancer agent is selected from the group consisting of cisplatin, carboplatin, paclitaxel, gemcitabine, doxorubicin, camptothecin, topotecan, and any combinations thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the combination of the compound of formula (I) and the anti-cancer agent reduces cancer cell proliferation.

### Claim 9

A method of inhibiting loss of cancer remission comprising contacting an individual having cancer with an effective amount of formula (I):
wherein
R1, R3 and R4 are independently hydrogen, hydroxy, halo, haloalkyl, NR12R13, C1-6 alkoxy, C1-6 fluoroalkyl or C1-6 alkyl;
R2 and R5 are independently hydrogen, hydroxy, halo, haloalkyl, NR12R13, C1-6 alkoxy, C1-6 fluoroalkyl or C1-6 alkyl;
R6 is hydrogen;
R7 is hydrogen, haloalkyl, halo or C1-6 alkyl;
R9 is hydroxy or C1-6 alkoxy;
R10 is hydrogen;
the drawing “” and R11 together represent a double bond or the drawing “” represents a single bond and R11 is hydrogen or hydroxy; and
R12 and R13 are independently hydrogen, C1-6 alkyl or trialkyl silyl;
or salts or a derivative thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the individual is in remission from bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, cancers of the brain or melanoma.

### Claim 11 (depends on 9)

The method of claim 9, wherein the individual is in remission from ovarian cancer or breast cancer.

### Claim 12 (depends on 9)

The method of claim 9, further comprising administering to the individual an anti-cancer agent.

### Claim 13

(canceled)

### Claim 14 (depends on 12)

The method of claim 12, wherein the anti-cancer agent is selected from the group consisting of cisplatin, carboplatin, paclitaxel, gemcitabine, doxorubicin, camptothecin, topotecan, and any combinations thereof.

### Claim 15

A method of inducing apoptosis in a cancer-related stem cell, the method comprising contacting said stem cell with a compound of formula (I):
wherein
R1, R3 and R4 are independently hydrogen, hydroxy, halo, haloalkyl, NR12R13, C1-6 alkoxy, C1-6 fluoroalkyl or C1-6 alkyl;
R2 and R5 are independently hydrogen, hydroxy, halo, haloalkyl, NR12R13, C1-6 alkoxy, C1-6 fluoroalkyl or C1-6 alkyl;
R6 is hydrogen;
R7 is hydrogen, haloalkyl, halo or C1-6 alkyl;
R9 is hydroxy or C1-6 alkoxy;
R10 is hydrogen;
the drawing “” and R11 together represent a double bond or the drawing “” represents a single bond and R11 is hydrogen or hydroxy; and
R12 and R13 are independently hydrogen, C1-6 alkyl or trialkyl silyl;
or salts or a derivative thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the individual is in remission from bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, cancers of the brain or melanoma.

### Claim 17 (depends on 15)

The method of claim 15, wherein the individual is in remission from ovarian cancer or breast cancer.

### Claim 18 (depends on 15)

The method of claim 15, further comprising administering to the individual an anti-cancer agent.

### Claim 19

(canceled)

### Claim 20 (depends on 18)

The method of claim 18, wherein the anti-cancer agent is selected from the group consisting of cisplatin, carboplatin, paclitaxel, gemcitabine, doxorubicin, camptothecin, topotecan, and any combinations thereof.

### Claim at position 21

-38. (canceled)
